Latanoprost Polpharma (Latanoprost)

Latanoprost binds to prostaglandin F (FP) receptors in the eye, stimulating the uveoscleral outflow pathway. This increased drainage of aqueous humor reduces intra‑ocular pressure, which is the primary therapeutic target in glaucoma and ocular hypertension.

The prescribed dose of Latanoprost Polpharma is determined by the treating ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but exact dosing and administration schedule should follow the prescriber’s instructions.

The safety of Latanoprost in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and use should be considered only if the potential benefit justifies the potential risk to the fetus or infant. Consultation with a healthcare professional is essential.

To order Latanoprost Polpharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally provides greater intra‑ocular pressure reduction with once‑daily dosing compared with beta‑blockers or carbonic anhydrase inhibitors. It is often preferred as first‑line therapy due to its efficacy and convenient dosing, though individual response and tolerance may vary.

Latanoprost Polpharma should be stored at room temperature, below 25 °C, in its original container. Protect the solution from light and moisture, and keep the cap tightly closed when not in use to maintain stability.

Latanoprost Polpharma is applied as a single drop into the conjunctival sac of the affected eye(s) once daily, preferably in the evening. The patient should wash hands before use, avoid touching the tip of the bottle to the eye or any surface, and close the eye gently after instillation.

Serious risks, though rare, include severe eye inflammation such as uveitis or iritis, allergic reactions with swelling or rash around the eye, sudden vision loss, and corneal edema. Any of these symptoms require immediate medical evaluation.

Latanoprost Polpharma should not be used by individuals with known hypersensitivity to Latanoprost or any component of the formulation, or by patients with active ocular infections. Caution is also advised for those who have had recent eye surgery until cleared by an ophthalmologist.